Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT02927054 Completed - Sepsis Clinical Trials

Effect of Education on Resident Physician Knowledge of Sepsis

Start date: July 2014
Phase: N/A
Study type: Interventional

A questionnaire was provided, including clinical vignettes and free text answers, to assess and evaluate the ability of resident physicians to identify systemic inflammatory response syndrome (SIRS), sepsis, and severe sepsis. Questionnaire scores were compared between specialties. A whole-hospital educational campaign was provided with the aim to improve sepsis recognition, and the questionnaire survey was repeated after one year to assess the effect of the education on the recognition of sepsis.

NCT ID: NCT02922998 Recruiting - Sepsis Clinical Trials

CD64 and Antibiotics in Human Sepsis

CD64SEPLDX
Start date: September 2016
Phase: N/A
Study type: Observational

The purpose of the study is to find out whether CD64 expression on neutrophils measured by a new bedside test (LeukoDx) within 30 minutes is associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis.

NCT ID: NCT02920736 Active, not recruiting - Sepsis Clinical Trials

Value of Urine sTREM-1 on Early Predicting AKI in Sepsis

Start date: January 2016
Phase: N/A
Study type: Observational

The purpose of this study is to determine the value of urine sTREM-1 on early predicting secondary acute kidney injury in sepsis

NCT ID: NCT02920593 Recruiting - Clinical trials for Gestational Hypertension

A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy

Start date: October 2016
Phase: Phase 4
Study type: Interventional

The investigators aim to determine if Vitamin D prophylaxis in pregnancy reduces the incidence of hypertensive disorders of pregnancy.

NCT ID: NCT02910765 Not yet recruiting - Sepsis Clinical Trials

Methylene Blue and Ozone in Early Sepsis

Start date: October 2016
Phase: Phase 4
Study type: Interventional

effects of methylene blue and ozone O3 therapy effects in early sepsis management , and their implications upon outcome

NCT ID: NCT02903082 Terminated - Severe Sepsis Clinical Trials

Following of Myeloid-derived Suppressor Cells (MDSC) in Severe Sepsis: What Relationship With Systemic Inflammatory Syndrome?

MDSC
Start date: April 2015
Phase:
Study type: Observational

Sepsis remains a major cause of death in developed countries. A better understanding of the mechanisms involved in the regulation of inflammatory and immune response of patients with severe sepsis is an important step that could open the way for new therapeutic approaches.

NCT ID: NCT02899143 Recruiting - Sepsis Clinical Trials

Short-course Antimicrobial Therapy in Sepsis

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the effect of a short course antimicrobial therapy (5-days) versus a 10-days therapy on sepsis-related organ dysfunction.

NCT ID: NCT02898961 Completed - Sepsis Clinical Trials

Impact of 30 mg/kg Amikacin and 8 mg/kg Gentamicin on Serum Concentrations in Critically Ill Patients With Severe Sepsis

Aminoside_II
Start date: October 2014
Phase: Phase 4
Study type: Interventional

Low first-dose peak serum concentrations of amikacin and gentamicin are commonly reported in ICU patients. The present study aimed to assess whether 30 mg/kg amikacin or 8 mg/kg gentamicin achieved target concentrations in ICU patients with severe sepsis.

NCT ID: NCT02891174 Completed - Pre-eclampsia Clinical Trials

The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy

Start date: December 1, 2016
Phase: Phase 4
Study type: Interventional

To assess the effect of routine doses of ibuprofen on post-partum blood pressure control in women with gestational hypertension (gHTN) or preeclampsia without severe features (preE).

NCT ID: NCT02887274 Recruiting - Sepsis Clinical Trials

Application of Stimulated Immune Response Change to Predict Outcome of Patient With Severe Sepsis

SIRCSS
Start date: July 2013
Phase:
Study type: Observational

Persistence of a marked compensatory anti-inflammatory innate immune response after an insult is termed immunoparalysis. There is no biomarker available to determine the immune status of patient. Thus, the need for early and definite diagnosis of immune status of patient with sepsis, as well as the identification of patients at risk of evolving with severe organ dysfunctions, is crucial. Most important of all, speed is the key to survival. Therefore, it of crucial importance to identify which patient characteristic determines the poor prognosis. Early intervention can improve the prognosis. Investigators foresee an urgent need to identify predictors for mortality in severe sepsis, including clinical factors or immune status. Recently, the PIRO model has been proposed as a way of stratifying septic patients according to their Predisposing condition, the severity of Infection, the Response to therapy and the degree of Organ dysfunction. The immune status may be associated with above model. However, there is paucity data addressing this issue. In this study, investigators will also analyze the progression of patient condition during treatment and the associated immune status change. In the future, Investigators hope the determination of immune status may contribute to this model of classification rather than just being used as prognostic markers. Despite the advances in the knowledge of the basic processes that trigger and sustain the systemic inflammatory response in sepsis, the search for a "magic bullet" to treat this syndrome has been frustrating. The incidence of severe sepsis and septic shock still remains quite high, as does its mortality, which has decreased very little over the past decades.